# HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis

> **NCT03456817** · PHASE2 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 68 (actual)

## Conditions studied

- Graft-versus-host-disease
- Relapse

## Interventions

- **DRUG:** Treatment Arm - high dose ATG
- **DRUG:** Control Arm - standard of care

## Key facts

- **NCT ID:** NCT03456817
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-01
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Slow patient accrual and appearance of a toxicity
- **Last updated:** 2025-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03456817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03456817, "HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03456817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*